Tuesday, January 09, 2018 8:27:54 AM
“A bank would never get away with what the Department of Education is doing.”
Sheila Bair
Recent CLLS News
- Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend] • Edgar (US Regulatory) • 09/11/2024 08:30:27 PM
- Cellectis Presents Pre-Clinical Evidence of MUC1 CAR T-cells Reducing Triple-Negative Breast Cancer While Preserving Safety • GlobeNewswire Inc. • 09/03/2024 08:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/26/2024 08:31:14 PM
- Cellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Recalcitrant Solid Tumors • GlobeNewswire Inc. • 08/26/2024 08:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/07/2024 10:00:06 AM
- Cellectis Appoints Dr. Adrian Kilcoyne as Chief Medical Officer • GlobeNewswire Inc. • 08/07/2024 06:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/06/2024 08:30:04 PM
- Cellectis Provides Financial Results for the Second Quarter 2024 • GlobeNewswire Inc. • 08/06/2024 08:30:00 PM
- FDA Grants Orphan Drug Designation to Cellectis’ CLLS52 (alemtuzumab) For ALL Treatment • GlobeNewswire Inc. • 08/01/2024 08:30:00 PM
- FDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis’ UCART22 product candidate for Acute Lymphoblastic Leukemia (ALL) Treatment • GlobeNewswire Inc. • 07/25/2024 08:30:00 PM
- Cellectis Reports Results from Shareholders Meeting Held on June 28, 2024 • GlobeNewswire Inc. • 06/28/2024 08:30:00 PM
- Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base Editing • GlobeNewswire Inc. • 06/20/2024 08:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/12/2024 08:35:05 PM
- Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications • GlobeNewswire Inc. • 06/12/2024 08:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/04/2024 08:41:02 PM
- Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic Leukemia • GlobeNewswire Inc. • 06/04/2024 08:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/29/2024 08:35:05 PM
- Cellectis’ Annual Shareholders General Meeting to be Held on June 28, 2024 • GlobeNewswire Inc. • 05/29/2024 08:30:00 PM
- Cellectis Reports Financial Results for First Quarter 2024 • GlobeNewswire Inc. • 05/28/2024 08:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/28/2024 10:00:10 AM
- Cellectis to Report First Quarter 2024 Financial Results on May 28, 2024 • GlobeNewswire Inc. • 05/27/2024 08:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/24/2024 08:06:01 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/06/2024 10:00:09 AM
- Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca • GlobeNewswire Inc. • 05/06/2024 06:00:00 AM
- Cellectis Appoints Arthur Stril as Interim Chief Financial Officer • GlobeNewswire Inc. • 05/02/2024 08:30:00 PM
FEATURED Nightfood Signs Letter of Intent to Acquire Los Angeles Cooking School, Integrating Automation and Robotics with World-Class Culinary Training • Oct 1, 2024 8:30 AM
FEATURED ZenaTech, Inc. (NASDAQ: ZENA) To Commence Trading Today • Oct 1, 2024 7:00 AM
Integrated Ventures, Inc Reports Total 2024 Revenues Of $5,863,935 vs $3,862,849 for 2023. • INTV • Oct 1, 2024 9:00 AM
Element79 Gold Corp secures loi for launching tailings reprocessing business in Arequipa, Peru • ELMGF • Oct 1, 2024 6:38 AM
BARRON'S COVE to Premier at the Hamptons International Film Festival • APHP • Sep 30, 2024 2:56 PM
Lingerie Fighting Championships Signs Broadcast Deal With Maybacks Global Entertainment • BOTY • Sep 26, 2024 9:00 AM